Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

IMI
Thematic Poster Session

TPS04--Advances in Anti-Infectives & Anti-Inflammatories

Friday, September 27, 2024
10:15 AM – 11:45 AM ET
Location:Theater A (Exhibit & Poster Hall)

This session will consist of two key components: (1) poster viewing followed by a (2) moderated discussion.

Learning Objectives:

  • Describe novel anti-infectives for CF pathogens currently in development.
  • Identify anti-inflammatory agents in use and under evaluation.
  • Discuss therapeutic strategies under investigation for treatment of pulmonary exacerbations and CF pathogens.

Presentations:

  • 10:15 AM – 11:45 AM ET
    ELD403 as a Novel Anti-Viral Therapy for RSV-related Infections in Cystic Fibrosis

    Speaker: Matthew Biggart, PhD (he/him/his) – Kansas University Medical Center

  • 10:15 AM – 11:45 AM ET
    ATP12A as an anti-inflammatory in CF primary epithelial cells

    Speaker: Tori Endres, MD (she/her/hers) – Rainbow Babies and Children's Hospital

  • 10:15 AM – 11:45 AM ET
    Differential effects of cationic antimicrobials on intrinsic antibiotic resistance in Pseudomonas aeruginosa

    Speaker: John S. Albin, MD, PhD – Massachusetts General Hospital

  • 10:15 AM – 11:45 AM ET
    Airway Clearance and Antibiotic Selection for Pulmonary Exacerbations in the STOP PEDS Pilot Study

    Speaker: Daphne Cheng, MD (she/her/hers) – University of Washington

  • 10:15 AM – 11:45 AM ET
    Comparison of clinical outcomes in infants with cystic fibrosis (CF) on ‘as-required’ and prophylactic antibiotics

    Speaker: Niamh Allison, MBChB (she/her/hers) – NHS Grampian, Scotland; University of Aberdeen, Scotland; University of Melbourne, Australia

  • 10:15 AM – 11:45 AM ET
    Trends of inhaled antibiotic prescription for non-chronic and chronic P. aeruginosa infection

    Speaker: Marianne Muhlebach (she/her/hers) – University of North Carolina at Chapel Hill

  • 10:15 AM – 11:45 AM ET
    MEK1/2 inhibitor ATR-002 has dual anti-inflammatory and anti-bacterial effects during S. aureus infection

    Speaker: Eryn N. Zuiker (she/her/hers) – The Ohio State University

  • 10:15 AM – 11:45 AM ET
    Antibiotic Selection for the STOP360-AG Randomized Controlled Trial

    Speaker: Jonathan D. Cogen, MD, MPH (he/him/his) – University of Washington

  • 10:15 AM – 11:45 AM ET
    TPS04.9- ACE-1b, a novel anti-infective conjugated electrolyte, effectively controls nontuberculous mycobacterial infections

    Speaker: Ken C. Malcolm – National Jewish Health

  • 10:15 AM – 11:45 AM ET
    Airway and systemic inflammatory response to oral prednisone during cystic fibrosis pulmonary exacerbations

    Speaker: Bradley S. Quon – Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada